Advanced search
Publication Cover
Future Microbiology Volume 1, 2006 - Issue 3
Submit an article Journal homepage
162
Views
0
CrossRef citations to date
0
Altmetric
Perspective

Controversies in the Treatment of Pneumococcal Community-Acquired Pneumonia

Charles Feldmana University of the Witwatersrand Medical School, Division of Pulmonology, Department of Medicine, 7 York Road, Parktown, 2193, Johannesburg, South Africa.Tel: + Fax: [email protected]
&
Ronald Andersonb MRC Unit for Inflammation & Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria, South Africa and, Tshwane Academic Division of the National Health Laboraty Service, South Africa.Tel: +27 12 319 2425 Fax: +27 12 323 [email protected]
Pages 271-281 | Published online: 09 Oct 2006

Bibliography

  • File TM Jr: Community-acquired pneumonia. Lancet362 , 1991–2001 (2003).
  • Fuller JD , McGeerA, LowDE: Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management.Eur. J. Clin. Microbiol. Infect. Dis.24 , 780–788 (2005).
  • Metlay JP , SingerDE: Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance.Clin. Microbiol. Infect.8(Suppl. 2) , 1–11 (2002).
  • Feldman C : Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.J. Lab. Clin. Med.143(5) , 269–283 (2004).
  • Metlay JP : Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes.Curr. Opinion. Infect. Dis.15 , 163–167 (2002).
  • Aspa J , RajasO, de Castro FR et al.; On behalf of the Pneumococcal Pneumonia in Spain Study Group: Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin.  Infect. Dis.38(6) , 787–798 (2004).
  • Lynch JP 3rd, Zhanel GG: Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy. Semin. Respir. Crit. Care Med.26(6) , 575–616 (2005).
  • Metlay JP : Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia.Infect. Dis. Clin. North. Am.18(4) , 777–790 (2004).
  • Chiou CC : Does penicillin remain the drug of choice for pneumococcal pneumonia in view of emerging in vitro resistance?Clin. Infect. Dis.42 , 234–237 (2006).
  • Lujan M , GallegoM, FontanalsD, Mariscal D, Rello J: Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality. Crit. Care Med.32(3) , 625–631 (2004).
  • Yu VL , ChiouCC, FeldmanC et al.; For the International Pneumococcal Study Group: An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered and clinical outcome. Clin. Infect. Dis.37 , 230–237 (2003).
  • Song JH , JungSI, KiHK et al.: Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin. Infect. Dis.38 , 1570–1578 (2004).
  • File TM , LodeH, KurzH, KozakR, XieH, BerkowitzE: Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin (2000/125 milligrams) versus those of amoxicillin–clavulanate (875/125 milligrams) both given twice daily for 7 days in treatment of bacterial community-acquired pneumonia in adults.Antimicrob. Agents Chemother.48(9) , 3323–3331 (2004).
  • Bonnard P , LescureFX, DouadiY et al.: Community-acquired pneumonia bacteraemic pneumococcal pneumonia in adults: effect of diminished penicillin susceptibility on clinical outcome. J. Infect.51 , 69–76 (2005).
  • Klugman KP , FeldmanC: Streptococcus pneumoniae respiratory tract infections.Curr. Opinion. Infect. Dis.14 , 173–179 (2001).
  • Turett GS , BlumS, FazalBA, JustmanJE, TelzakEE: Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence.Clin. Infect. Dis.29 , 321–327 (1999).
  • Feikin DR , SchuchatA, KolczakM et al.: Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am. J. Public. Health90 , 223–229 (2000).
  • Metlay JP , HofmannJ, CetronMS et al.: Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis.30 , 520–528 (2000).
  • Falco VV , AlmiranteB, JordanoQ et al.: Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains? J. Antimicrob. Chemother.54(2) , 481–488 (2004).
  • Tleyjeh IM , TlaygehHM, HejalR, Montori VM, Baddour LM: The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin. Infect. Dis.42 , 778–797 (2006).
  • File TM Jr, Tan JS, Boex JR: The clinical relevance of penicillin-resistant Streptococcus pneumoniae: a new perspective. Clin. Infect. Dis.42 , 798–800 (2006).
  • Peterson LR : Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?Clin. Infect. Dis.42 , 224–233 (2006).
  • Garau J : Role of β-lactam agents in the treatment of community-acquired pneumonia.Eur. J. Clin. Microbiol. Infect. Dis.24 , 83–99 (2005).
  • Klugman KP , LonksJR: Hidden epidemic of macrolide-resistant pneumococci.Emerg. Infect. Dis.11(6) , 802–807 (2005).
  • Rzeszutek M , WierzbowskiA, HobanDJ, ConlyJ, BishaiW, ZhanelGG: A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae.Int. J. Antimicrob. Agents24(2) , 95–104 (2004).
  • Amsden GW : Pneumococcal macrolide resistance – myth or reality?J. Antimicrob. Chemother.44 , 1–6 (1999).
  • Feldman C , BrinkAJ, RichardsGR et al.: Management of community-acquired pneumonia in adults. S. Afr. Med. J.92(8 Pt 2) , 647–655 (2002).
  • Volturo GA , LowDE, AghababianR: Managing acute lower respiratory tract infections in an era of antibacterial resistance.Am. J. Emerg. Med.24(3) , 329–342 (2006).
  • Fuller JD , LowDE: A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.Clin. Infect. Dis.41 , 118–121 (2005).
  • Ambrose PG , BastD, DoernGV et al.: Fluoroquinolone-resistant Streptococcus pneumoniae, an emerging but unrecognized public health concern: is it time to resight the goalposts? Clin. Infect. Dis.39 , 1554–1556 (2004).
  • Lim S , BastD, McGeerA, de Azavedo J, Low DE: Antimicrobial susceptibility breakpoints of first-step parC mutants in Streptococcus pneumoniae redefing fluoroquinolone resistance. Emerg. Infect. Dis.9(7) , 833–837 (2003).
  • Vanderkooi OG , LowDE, GreenK, Powis JE, McGeer A; For the Toronto Invasive Bacterial Disease Network: Predicting antimicrobial resistance in invasive pneumococcal infections. Clin. Infect. Dis.40 , 1288–1297 (2005).
  • Gleason PP , MeehanTP, FineJM, Galusha DH, Fine MJ: Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Intern. Med.159 , 2562–2572 (1999).
  • Weiss K , TillotsonGS: The controversy of combination versus monotherapy in treatment of hospitalized community-acquired pneumonia.Chest 128 , 940–946 (2005).
  • Waterer GW : Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia.Curr. Opinion. Infect. Dis.18 , 157–163 (2005).
  • Mufson MA , StanekRJ: Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997.Am. J. Med.107(1A) , S34–S43 (1999).
  • Waterer GW , SomesGW, WunderinkRG: Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.Arch. Intern. Med.161 , 1837–1842 (2001).
  • Martinez JA , HorcajadaJP, AlmelaM et al.: Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis.36 , 389–395 (2003).
  • Baddour LM , YuVL, KlugmanKP et al.; and the International Pneumococcal Study Group: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am. J. Respir. Crit. Care Med.170 , 440–444 (2004).
  • Weiss K , LowDE, CortesL et al.: Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can. Respir.  J.11(8) , 589–593 (2004).
  • Garcia Vazquez VE , MensaJ, MartinezJA et al.: Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a β-lactam agent versus a β-lactam agent alone. Eur. J. Clin. Microbiol. Infect. Dis.24(3) , 190–195 (2005).
  • Epstein BJ , GumsJG: Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.Drugs65(14) , 1949–1971 (2005).
  • Harbarth S , GarbinoJ, PuginJ, Romand JA, Pittet D: Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur. J. Clin. Microbiol. Infect. Dis.24 , 688–690 (2005).
  • Aspa J , RajasO, Rodriguez de Castro F et al.; On behalf of the Pneumococcal Pneumonia in Spain Study Group: Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur. Respir. J.27 , 1010–1019 (2006).
  • Torres A : Monotherapy in severe community-acquired pneumonia. Is it worthy?Chest128(1) , 10–13 (2005).
  • Finch R , SchurmannD, CollinsO et al.: Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob. Agents Chemother.46(6) , 1746–1754 (2002).
  • Portier H , BrambillaC, GarreM, PaganinF, PoubeauP, ZuckP: Moxifloxacin monotherapy compared to amoxicillin–clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.Eur. J. Clin. Microbiol. Infect. Dis.24(6) , 367–376 (2005).
  • Katz E , LarsenS, FogartyCM, HamedK, SongJ, ChoudhriS: Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.J. Emerg. Med.27(4) , 395–405 (2004).
  • Welte T , PetermannW, SchuermannD, BauerTT, ReimnitzP, and the MOXIRAPID Study Group: Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parental therapy. Clin. Infect. Dis.41 , 1697–1705 (2005).
  • Mortensen EM , RestrepMI, AnzuetoA, PughJ: The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.Crit. Care DOI 10.1186/cc3934 (2006) (Epub ahead of print).
  • Waterer GW : Optimal antibiotic treatment in severe pneumococcal pneumonia – time for real answers.Eur. J. Clin. Microbiol. Infect. Dis.24 , 691–692 (2005).
  • Waterer GW , RelloJ: Choosing the right combination therapy in severe community-acquired pneumonia.Crit. Care10(1) , 115 DOI 10.1186/cc3976 (2006) (Epub ahead of print).
  • Shefet D , RobenshtokE, PaulM, Leibovici L: Empirical atypical coverage for inpatients with community-acquired pneumonia. Systematic review of randomized controlled trials. Arch. Intern. Med.165 , 1992–2000 (2005).
  • Mills GD , OehleyMR, ArrolB: Effectiveness of β-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community-acquired pneumonia: meta-analysis.Br. Med. J.330(7489) , 456 (2005).
  • Johansen HK , JensenTG, DessauRB, LundgrenB, Frimodt-MollerN: Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo.J. Antimicrob. Chemother.46 , 973–980 (2000).
  • Jedrzejas M : Pneumococcal virulence factors: structure and function.Microbiol. Mol. Biol. Rev.65 , 187–207 (2001).
  • Kwon HY , OgunniyiAD, ChoiMH, Pyo SN, Rhee DK, Paton JC: The ClpP protease of Streptococcus pneumoniae modulates virulence gene expression and protects against fatal pneumococcal challenge. Infect. Immun.72 , 5646–5653 (2004).
  • Orihuela CJ , GaoG, FrancisKP, YuJ, TuomanenEI: Tissue-specific contributions of pneumococcal virulence factors to pathogenesis.J. Infect. Dis.190 , 1661–1669 (2004).
  • Manco S , HernonF, YesilkayaH, PatonJC, AndrewPW, KadiogluA: Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis.Infect. Immun.74 , 4014–4020 (2006).
  • Cockeran R , AndersonR, FeldmanC: Pneumolysin in the immunopathogenesis and treatment of pneumococcal disease.Expert Rev. Anti-Infect. Ther.1(2) , 231–239 (2003).
  • Witzenrath M , GutbierB, HockeAC et al.: Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit. Care Med.34(7) , 1947–1954 (2006).
  • Kirkham LA , JeffriesJM, KerrAR et al.: Identification of invasive serotype 1 pneumococcal isolates that express nonhaemolytic pneumolysin. J. Clin. Microbiol.44 , 151–159 (2006).
  • Van Rossum AM , LysenkoES, WeiserJN: Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneumoniae in a murine model.Infect. Immun.73 , 7718–7726 (2005).
  • Ratner AJ , HippeKR, AguilarJL, Bender MH, Nelson AL, Weiser JN: Epithelial cells are sensitive detectors of bacterial pore-forming toxins. J. Biol. Chem.281 , 12994–12998 (2006).
  • Jounblat R , KadiogluA, MitchellTJ, AndrewPW: Pneumococcal behavior and host responses during bronchopneumonia are affected differently by the cytolytic and complement-activating activities of pneumolysin.Infect. Immun.71 , 1813–1819 (2003).
  • Maus UA , SrivastavaM, PatonJC et al.: Pneumolysin-induced lung injury is independent of leukocyte trafficking into the alveolar space. J. Immunol.173 , 1307–1312 (2004).
  • Moreland JG , BaileyG: Neutrophil transendothelial migration in vitro to Streptococcus pneumoniae is pneumolysin dependent.Am. J. Physiol. Lung Cell Mol. Physiol.290 , L833–L840 (2006).
  • Cockeran R , DurandtC, FeldmanC, MitchellTJ, AndersonR: Pneumolysin activates the synthesis and release of interleukin-8 by human neutrophils in vitro.J. Infect. Dis.186 , 562–565 (2002).
  • Cockeran R , TheronAJ, FeldmanC, MitchellTJ, AndersonR: Pneumolysin potentiates oxidative inactivation of α-1-proteinase inhibitor by activated human neutrophils.Respir. Med.98 , 865–871 (2004).
  • Fickl H , CockeranR, SteelHC et al.: Pneumolysin-mediated activation of NFκB in human neutrophils is antagonized by docosahexaenoic acid. Clin. Exp. Immunol.140 , 274–281 (2005).
  • Malley R , HennekeP, MorseSC et al.: Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl Acad. Sci. USA100 , 1966–1971 (2003).
  • Spreer A , KerstanH, BöttcherT et al.: Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone. Antimicrob. Agents Chemother.47 , 2649–2654 (2003).
  • Hirst RA , MohammedBJ, MichellTJ, AndrewPW, O‘CallaghanC: Streptococcus pneumoniae-induced inhibition of rat ependynal cilia is attenuated by antipneumolysin antibody.Infect. Immun.72 , 6694–6698 (2004).
  • Amsden GW : Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of community acquired respiratory tract infections and chronic pulmonary conditions.J. Antimicrob. Chemother.55 , 10–21 (2005).
  • Shinkai M , Sik Park C, Rubin BK: Immunomodulatory effects of macrolide antibiotics. Clin. Pulm. Med.12 , 341–348 (2005).
  • Feldman C , AndersonR: The cytoprotective interactions of antibiotics with human ciliated airway epithelium. In:Antibiotics as Anti-Inflammatory and Immunomodulatory Agents. Rubin BK, Tamaoki J (Eds). Birkhauser Verlag, Basel, Switzerland 49–63 (2005).
  • Lagrou K , PeetermansWA, JorrisenM, VerhaegenJ, Van Damme J, Van Eldere J: Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro. J. Antimicrob. Chemother.46 , 717–723 (2000).
  • Fukuda Y , YanagiharaK, HigashiyamaY et al.: Effects of macrolides against pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur. Respir. J.27 , 1020–1025 (2006).
  • Tateda K , IshiiY, MatsumotoT, KobayashiT, MiyazakiS, YamaguchiK: Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response.J. Infect Chemother.6 , 1–7 (2000).
  • Du Cheyron D , LesageA, Le Page O, Flais F, Leclercq R, Charbonneau P: Corticosteroids as adjunctive treatment in Austrian‘s syndrome (pneumococcal endocarditis, meningitis and pneumonia): report of two cases and review of the literature. J. Clin. Pathol.56 , 879–881 (2003).
  • Wasier AP , ChevretL, EssouriS, DurandP, ChevretS, DevictorD: Pneumococcal meningitis in a pediatric intensive care unit: prognostic factors in a series of 49 children.Pediatr. Crit. Care Med.6 , 568–572 (2005).
  • McIntyre P : Should dexamethasone be part of routine therapy of bacterial meningitis in industrialised countries?Adv. Exp. Med. Biol.568 , 189–197 (2005).
  • McIntosh ED : Treatment and prevention strategies to combat paediatric pneumococcal meningitis.Expert Rev. Anti-Infect. Therapy3 , 739–750 (2005).
  • Confalonieri M , UrbinoR, PotenaA et al.: Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am. J. Respir. Crit. Care Med.171 , 242–248 (2005).
  • Christ-Crain M , StolzD, BingisserR et al.: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia. A randomized trial. Am. J. Respir. Crit. Care Med.174 , 84–93 (2006).
  • Annane D , SebilleV, CharpentierC et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA288 , 862–871 (2002).
  • Annane D , BellissantE, BollaertPE, Briegel J, Keh D, Kupfer Y: Corticosteroids for treating severe sepsis and septic shock. Cochrane Database Syst. Rev.CD002243 (2004).
  • Oppert M , SchindlerR, HusungC et al.: Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit. Care Med.33 , 2457–2464 (2005).
  • Annane D , SebilleV, Bellissant E; Ger-Inf-05 Study Group: Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit. Care Med.34 , 22–30 (2006).
  • Steinberg KP , HudsonLD, GoodmanRB et al.: Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N. Engl. J. Med.354 , 1671–1684 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.